BCRX
BioCryst Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +5.4% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 109 | +4 | 139.04M | $1.39B | +8 | −4 |
| Q1 2026 | 108 | +4 | 130.67M | $1.24B | +14 | −10 |
| Q4 2025 | 103 | -1 | 127.11M | $991.41M | — | −1 |
| Q3 2025 | 22 | +2 | 89.66M | $680.51M | +2 | −1 |
| Q2 2025 | 18 | +1 | 80.75M | $723.56M | +1 | — |
| Q1 2025 | 14 | +1 | 26.41M | $198.06M | +1 | — |
| Q4 2024 | 13 | -2 | 21.17M | $159.22M | — | −2 |
| Q3 2024 | 14 | +4 | 16.62M | $126.32M | +4 | — |
| Q2 2024 | 10 | — | 15.77M | $97.44M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 4.84M | +2.7% | $36.78M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 4.84M | +2.7% | $36.78M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Fisher Asset Management ✦ | 3.34M | +16.9% | $25.37M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 2.25M | +15.6% | $17.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 2.25M | +15.6% | $17.12M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 1.76M | +5.2% | $13.38M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Millennium Management ✦ | 1.32M | -24.5% | $10.05M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 787.23K | +44.9% | $5.98M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 787.23K | +44.9% | $5.98M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 787.23K | +44.9% | $5.98M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 611.90K | -6.1% | $4.65M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 589.08K | -38.6% | $4.48M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 431.23K | New | $3.28M | 0.0% | New | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 279.14K | -12.2% | $2.12M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 279.14K | -12.2% | $2.12M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 229.09K | -34.7% | $1.74M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Wellington Management ✦ | 107.82K | New | $819,432 | 0.0% | New | 1 | SEC ↗ |
| 18 | Wellington Management ✦ | 107.82K | New | $819,432 | 0.0% | New | 1 | SEC ↗ |
| 19 | Wellington Management ✦ | 107.82K | New | $819,432 | 0.0% | New | 1 | SEC ↗ |
| 20 | Wellington Management ✦ | 107.82K | New | $819,432 | 0.0% | New | 1 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 38.89K | New | $295,587 | 0.0% | New | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 33.26K | New | $252,753 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $3.28M | 0.0% |
| Wellington Management | $819,432 | 0.0% |
| Wellington Management | $819,432 | 0.0% |
| Wellington Management | $819,432 | 0.0% |
| Wellington Management | $819,432 | 0.0% |
| Gotham Asset Management | $295,587 | 0.0% |
| Marshall Wace | $252,753 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 298 holders, 245.96M shares, $2.30B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.